Company intelligence / Profile preview
Navamedic ASA
Oslo, Norwaynavamedic.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Navamedic reported strong Q1 2025 results with revenues of NOK 132.0 million (9.2% increase from Q1 2024), EBITDA of NOK 12.8 million (up from NOK 8.5 million), and improved gross margin of 40.7% (compared to 38.7% in Q1 2024)[4]. The company has secured two long-term Nordic tenders for its antibiotics portfolio in 2024[4].
- Therapeutic areas
- Men's HealthEndocrinologyCardiovascularNeurology
- Modalities
- Prescription drugsConsumer health productsHospital products
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Orion Corp (for distribution of Flexilev)Alex Therapeutics (for development of a companion app)
Beyond the preview
Go deeper on Navamedic ASA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Navamedic ASA.